Thursday, August 21, 2014
AstraZeneca plc has unveiled
plans for the R&D center and global headquarters it will build in
Cambridge, U.K.-the next major step in the pharma's strategy to improve
pipeline productivity that it hopes will help it recover growth and regain
ground in scientific leadership. The company expects that the new center will
drive therapeutic innovation by allowing it to tap world-class research through
partnerships with nearby institutes.
said that the new R&D center builds on existing collaborations the pharma
already has in Cambridge, and "as our presence in Cambridge grows over the
next few years-and we establish ourselves as a great scientific partner-I
believe we will see further opportunities for both formal and informal
interactions" with researchers at neighboring institutions.
M.J. SciBX 7(32); doi:10.1038/scibx.2014.942
Published online Aug. 21, 2014
1. Boettner, B. et al.
SciBX 7(29); doi:10.1038/scibx.2014.849
Addenbrooke's Hospital, Cambridge, U.K.
(LSE:AZN; NYSE:AZN), London, U.K.
Babraham Institute, Cambridge, U.K.
Cancer Research UK Cambridge Institute, Cambridge, U.K.
Medical Research Council, London, U.K.
MRC Laboratory of Molecular Biology, Cambridge, U.K.
University of Cambridge, Cambridge, U.K.
Wellcome Trust-MRC Institute of Metabolic Sciences, Cambridge, U.K.
Wellcome Trust Sanger Institute, Cambridge, U.K.